



Universiteit
Leiden
The Netherlands

Multi-gene panel testing and association analysis in Cypriot breast cancer cases and controls

Zanti, M.; Loizidou, M.A.; O'Mahony, D.G.; Dorling, L.; Dennis, J.; Devilee, P.; ... ;
Michailidou, K.

Citation

Zanti, M., Loizidou, M. A., O'Mahony, D. G., Dorling, L., Dennis, J., Devilee, P., ...
Michailidou, K. (2023). Multi-gene panel testing and association analysis in Cypriot breast
cancer cases and controls. *Frontiers In Genetics*, 14. doi:10.3389/fgene.2023.1248492

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3728557>

Note: To cite this publication please use the final published version (if applicable).



OPEN ACCESS

EDITED BY

Marta Olszewska,
Polish Academy of Sciences, Poland

REVIEWED BY

Zhi Ling Teo,
Peter MacCallum Cancer Centre,
Australia
Giovana Tardin Torrezan,
A.C.Camargo Cancer Center, Brazil

*CORRESPONDENCE

Kyriaki Michailidou,
✉ kyriakimi@cing.ac.cy

RECEIVED 27 June 2023

ACCEPTED 28 August 2023

PUBLISHED 18 September 2023

CITATION

Zanti M, Loizidou MA, O'Mahony DG,
Dorling L, Dennis J, Devilee P, Easton DF,
Panayiotidis MI, Hadjisavvas A and
Michailidou K (2023), Multi-gene panel
testing and association analysis in Cypriot
breast cancer cases and controls.
Front. Genet. 14:1248492.
doi: 10.3389/fgene.2023.1248492

COPYRIGHT

© 2023 Zanti, Loizidou, O'Mahony,
Dorling, Dennis, Devilee, Easton,
Panayiotidis, Hadjisavvas and Michailidou.
This is an open-access article distributed
under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).
The use, distribution or reproduction in
other forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Multi-gene panel testing and association analysis in Cypriot breast cancer cases and controls

Maria Zanti¹, Maria A. Loizidou², Denise G. O'Mahony¹,
Leila Dorling³, Joe Dennis³, Peter Devilee^{4,5}, Douglas F. Easton^{3,6},
Mihalis I. Panayiotidis², Andreas Hadjisavvas² and
Kyriaki Michailidou^{1,3*}

¹Biostatistics Unit, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus, ²Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus, ³Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom, ⁴Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Pathology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom

Introduction: It is estimated that around 5% of breast cancer cases carry pathogenic variants in established breast cancer susceptibility genes. However, the underlying prevalence and gene-specific population risk estimates in Cyprus are currently unknown.

Methods: We performed sequencing on a population-based case-control study of 990 breast cancer cases and 1094 controls from Cyprus using the BRIDGES sequencing panel. Analyses were conducted separately for protein-truncating and rare missense variants.

Results: Protein-truncating variants in established breast cancer susceptibility genes were detected in 3.54% of cases and 0.37% of controls. Protein-truncating variants in *BRCA2* and *ATM* were associated with a high risk of breast cancer, whereas PTVs in *BRCA1* and *PALB2* were associated with a high risk of estrogen receptor (ER)-negative disease. Among participants with a family history of breast cancer, PTVs in *ATM*, *BRCA2*, *BRCA1*, *PALB2* and *RAD50* were associated with an increased risk of breast cancer. Furthermore, an additional 19.70% of cases and 17.18% of controls had at least one rare missense variant in established breast cancer susceptibility genes. For *BRCA1* and *PALB2*, rare missense variants were associated with an increased risk of overall and triple-negative breast cancer, respectively. Rare missense variants in *BRCA1*, *ATM*, *CHEK2* and *PALB2* domains, were associated with increased risk of disease subtypes.

Conclusion: This study provides population-based prevalence and gene-specific risk estimates for protein-truncating and rare missense variants. These results may have important clinical implications for women who undergo genetic testing and be pivotal for a substantial proportion of breast cancer patients in Cyprus.

KEYWORDS

breast cancer susceptibility, panel sequencing, MASTOS study, case-control, next-generation sequencing

1 Introduction

Germline pathogenic variants (PVs) in cancer susceptibility genes have been associated with a significant risk of breast cancer (Dorling et al., 2021). Following the National Comprehensive Cancer Network (NCCN) guidelines, medical management recommendations are provided for certain genes contributing to increased risk of breast cancer (Daly et al., 2021). Genetic testing allows patients carrying PVs, to benefit from risk-reducing strategies including closer surveillance at an early age, prophylactic surgeries and chemoprevention, as well as targeted therapies (Pilie et al., 2019).

Gene panel testing of large population-based case-control studies has recently provided improved estimates of the prevalence of PVs and the respective magnitude of breast cancer risk associated with these PVs (Dorling et al., 2021; Hu et al., 2021). It is estimated that around 5% of breast cancer cases harbor PVs in established breast cancer susceptibility genes (*ATM*, *BARD1*, *BRCA1*, *BRCA2*, *CHEK2*, *PALB2*, *RAD51C*, *RAD51D*, *TP53*), of which the most prevalent occur in *BRCA2*, *CHEK2* and *BRCA1* (Dorling et al., 2021; Hu et al., 2021). Recently, it has been reported that 13% of high-risk Cypriot breast cancer patients are positive for PVs in *BRCA1* and *BRCA2* (Loizidou et al., 2017). However, the aggregate prevalence of cancer susceptibility genes among breast cancer cases or controls unselected for family history or age at diagnosis is not yet determined.

Here we used panel sequencing data generated as part of the Breast Cancer Association Consortium (BCAC) BRIDGES project (Dorling et al., 2021), to investigate the prevalence of PVs and rare missense variants in samples from the MASTOS study (Loizidou et al., 2008; Hadjisavvas et al., 2010), a population-based case-control study of breast cancer in Cyprus. We also estimated the risks of breast cancer associated with protein-truncating and rare missense variants in the Cypriot population.

2 Materials and methods

2.1 Study population

This study included case-control samples from the MASTOS study, a population-based case-control study of breast cancer in Cyprus (Loizidou et al., 2008; Hadjisavvas et al., 2010). The study was approved by the National Bioethics Committee of Cyprus, and all participants provided signed informed consent (Approval No, EEBK/EII/2016/38) (Loizidou et al., 2008). The study includes 990 breast cancer cases and 1,094 age-matched healthy controls. All study participants were over 18 years of age. The average age of diagnosis for cases was 51.5 ± 9.3 standard deviation (sd) years, while the average age at the time of study enrolment for age-matched controls, was 55.7 ± 6.9 sd. Positive family history of breast cancer was reported for 16.2% ($n = 158/973$) and 8.0% ($n = 87/1,091$) for cases and controls, respectively. The majority of tumors were invasive carcinomas (92.5%, $n = 656/709$), estrogen receptor (ER)-positive (75.8%, $n = 476/628$), progesterone receptor (PR)-positive (61.6%, $n = 381/619$) and human epidermal growth factor receptor 2 (HER2)-negative (83.9%, $n = 490/584$). Out of the 990 tumors, 576 (58.2%) had available data for all ER, PR and

HER2, of which 11.5% ($n = 66/576$) had a triple-negative phenotype, 76.6% ($n = 441/576$) had an ER + phenotype, 62.8% ($n = 362/576$) had a PR + phenotype and 16.1% ($n = 93/576$) had a HER2+ phenotype. All study sample characteristics are summarized in Table 1.

2.2 Sequence analysis

We analyzed targeted panel sequencing data on 35 actionable and suspected breast cancer susceptibility genes (Supplementary Table S1) using the BRIDGES panel (Dorling et al., 2021). Results are presented for variants in 34 genes since *PPM1D* was shown to be associated with breast or ovarian cancer risk, but in low allelic fractions (“somatic mosaicism”) (Ruark et al., 2013). These are potentially due to treatment, thus excluded from further analysis. Details on library preparation, sequencing and bioinformatics analysis including variant calling and quality control were previously documented (Dorling et al., 2021). In-frame insertions/deletions, intronic variants and variants in untranslated regions (UTRs) were not considered in the analysis.

Protein-truncating variants (PTVs) were defined as frameshift insertions/deletions, splicing variants (± 2 positions) and nonsense variants as annotated by ANNOVAR (Wang et al., 2010). Splice variants affecting the penultimate exon (except variants in *ATM*, *BARD1*, *BRCA1*, *RAD51C*, *RAD51D* and *PALB2* for which the truncated protein might still be pathogenic, irrespective of exon skipping; evidence previously documented (Dorling et al., 2021)), as well as PTVs in the last exon of each gene, were excluded from the analysis (Dorling et al., 2021). In addition, six canonical splice variants in *BRCA1* (c.594-2A>C, c.4096 + 1G>A, c.4096 + 2T>C, c.4186-2A>G, c.4358-1G>C and c.4358-2del) were excluded, since they are of uncertain clinical significance according to ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) classification schemes (Spurdle et al., 2012).

Classifications for rare missense variants (allele frequency of less than 0.001 in gnomAD v2.1.1 non-Finnish European exome samples) were retrieved from ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>, last accessed 11/12/2022), or the ENIGMA *BRCA1* and *BRCA2* expert panel (<https://enigmaconsortium.org/>) (Spurdle et al., 2012), along with missense *TP53* variant classification based on ACMG/AMP guidelines (Richards et al., 2015), augmented with classifications made using a quantitative classification model which utilizes bioinformatics prediction tools alongside germline to somatic frequency ratios (Fortuno et al., 2019; Fortuno et al., 2021). Rare missense variants were further annotated for functional protein domain location defined by the UniProt database (<https://www.uniprot.org/>, release 2022_04). Rare missense variants classified as (likely) benign were not considered in the analysis.

2.3 Statistical analysis

Prevalence of protein-truncating and rare missense variants in each gene was tabulated for breast cancer patients and controls.

TABLE 1 Study population characteristics.

Characteristics	Cases (N = 990)	Controls (N = 1,094)
Age ^a		
Mean ± sd—years	51.5 ± 9.3	55.7 ± 6.9
Range—years	26–74	28–71
Age Distribution—N/total N. (%)		
≤29	5/990 (0.5%)	2/1,091 (0.2%)
30–39	87/990 (8.8%)	8/1,091 (0.7%)
40–49	349/990 (35.3%)	178/1,091 (16.3%)
50–59	344/990 (34.7%)	566/1,091 (51.9%)
≥60	205/990 (20.7%)	337/1,091 (30.9%)
Family history of breast cancer ^b —N/total N. (%)		
No	815/973 (83.8%)	1,004/1,091 (92.0%)
Yes	158/973 (16.2%)	87/1,091 (8.0%)
Histological subtype—N/total N. (%)		
Invasive	656/709 (92.5%)	NA
<i>In situ</i>	53/709 (7.5%)	NA
ER status—N/total N. (%)		
ER-negative	152/628 (24.2%)	NA
ER-positive	476/628 (75.8%)	NA
PR status—N/total N. (%)		
PR-negative	238/619 (38.4%)	NA
PR-positive	381/619 (61.6%)	NA
HER2 status—N/total N. (%)		
HER2-negative	490/584 (83.9%)	NA
HER2-positive	94/584 (16.1%)	NA
Breast cancer subtypes ^c —N/total N. (%)		
Triple-negative	66/576 (11.5%)	NA
ER-positive	441/576 (76.6%)	NA
PR-positive	362/576 (62.8%)	NA
HER2-positive	93/576 (16.1%)	NA

^aAge is denoted as the age at diagnosis for cases or age at interview for controls.

^bfamily history was restricted to first-degree relatives.

^cbreast cancer subtypes for tumors that have data available for all ER, PR, and HER2 biomarkers.

Estrogen receptor; HER2, human epidermal growth factor receptor 2; NA, non-applicable; PR, progesterone receptor; sd, standard deviation.

Odds ratios (ORs) with 95% CIs were estimated using Firth's bias-reduced penalized-likelihood logistic regression for overall, ER-positive and ER-negative breast cancer. For ER-negative cases, we also evaluated the associations for triple-negative breast cancer. Associations were adjusted for age at diagnosis or interview and first-degree family history of breast cancer. Logistic regression *p* values were estimated using Wald's test. *p* values smaller than 0.05 were considered to be statistically significant. Association analysis was performed separately for PTVs and rare missense variants. Associations for rare missense variants were also

evaluated according to gene and gene domain for the established breast cancer susceptibility genes (Dorling et al., 2021). Heterozygous and homozygous carriers of variants in a gene were not distinguished as it was not always possible to do so with certainty, and the number of homozygotes was too small for separate analysis.

Cumulative risks of breast cancer in the absence of other events were calculated by combining age-specific odds ratios with population incidence rates for Cyprus (2020) as a baseline, as previously described (Schmidt et al., 2016).

TABLE 2 Prevalence of protein-truncating variants and associations with overall breast cancer risk.

Gene	Prevalence of PTVs			Adjusted OR (95% CI)	p-Value
	Variants	Carriers (N, %)			
		Cases (N = 990)	Controls (N = 1,094)		
Established breast cancer susceptibility genes					
<i>ATM</i>	7	9 (0.91)	1 (0.09)	7.61 (1.32–43.97)	0.023
<i>BRCA1</i>	1	3 (0.30)	1 (0.09)	3.18 (0.44–23.1)	0.25
<i>BRCA2</i>	6	18 (1.82)	1 (0.09)	9.75 (1.81–52.69)	0.0081
<i>CHEK2</i>	1	-	1 (0.09)	0.35 (0.01–8.69)	0.52
<i>PALB2</i>	1	5 (0.51)	-	16.14 (0.85–305.14)	0.0637
Other genes					
<i>CDH1</i>	1	-	1 (0.09)	0.31 (0.01–7.67)	0.48
<i>ABRAXAS1</i>	1	1 (0.10)	-	1.61 (0.07–39.77)	0.77
<i>FANCC</i>	2	3 (0.30)	2 (0.18)	1.06 (0.2–5.5)	0.94
<i>FANCM</i>	1	-	1 (0.09)	0.2 (0.01–4.97)	0.33
<i>GEN1</i>	1	-	1 (0.09)	0.2 (0.01–4.97)	0.33
<i>MRE11</i>	1	-	1 (0.09)	0.62 (0.03–15.18)	0.77
<i>MUTYH</i>	2	1 (0.10)	1 (0.09)	1.2 (0.12–11.77)	0.87
<i>RAD50</i>	1	4 (0.40)	1 (0.09)	3.83 (0.56–26.12)	0.17
<i>RECQL</i>	2	1 (0.10)	3 (0.27)	0.62 (0.08–4.71)	0.65
<i>RINT1</i>	1	-	1 (0.09)	0.26 (0.01–6.37)	0.41
Total	29	46 (4.65)	16 (1.46)		

For the established breast cancer susceptibility genes (Dorling et al., 2021) and other genes included in the panel, odds ratios (ORs) with 95% confidence intervals (CIs) were estimated by adjusting for age and family history of breast cancer (first-degree relatives) using the Firth's bias-reduced penalized-likelihood logistic regression. *p* values were estimated using the Wald's test. Significant risks (*p*-value < 0.05, OR > 1.0, CI, not including 1) of breast cancer overall, are indicated in bold. CI, confidence interval; OR, odds ratio; PTVs, protein-truncating variants.

3 Results

All the protein-truncating and rare missense variants are provided in Supplementary Table S2.

3.1 Protein-truncating variants


Among 990 breast cancer cases and 1,094 controls, we identified 27 unique PTVs in 4.55% (*n* = 45/990) of cases and 1.46% (*n* = 16/1,094) of controls (Table 2, Supplementary Table S2). Of these, 3.54% of cases (*n* = 35/990) and 0.37% of controls (*n* = 4/1,094), harbored PTVs in the established breast cancer susceptibility genes *ATM*, *BARD1*, *BRCA1*, *BRCA2*, *CHEK2*, *PALB2*, *RAD51C*, *RAD51D* and *TP53* (Dorling et al., 2021).

Among the case patients, the highest prevalence of PTVs was observed for *BRCA2* (*n* = 18/990, 1.82%), *ATM* (*n* = 9/990, 0.91%), *PALB2* (*n* = 5/990, 0.51%), *RAD50* (*n* = 4/990, 0.40%), *BRCA1* (*n* = 3/990, 0.3%) and *FANCC* (*n* = 3/990, 0.3%). We also identified one PTV in each of *RECQL*, *ABRAXAS1* and *MUTYH*. Among controls, the highest prevalence was observed for *RECQL* (*n* = 3/1,094, 0.27%)

and *FANCC* (*n* = 2/1,094, 0.18%). We also detected one PTV in each of *ATM*, *BRCA1*, *BRCA2*, *CDH1*, *CHEK2*, *FANCM*, *GEN1*, *MRE11*, *MUTYH*, *RAD50* and *RINT1* (Table 2). The founder *BRCA2* c.8756delG PTV was detected in 1.01% of breast cancer cases (*n* = 10/990) and 0.09% of controls (*n* = 1/1,094) which corresponds to more than half of the *BRCA2* PTVs observed among cases (55.56%, *n* = 10/18) and the only *BRCA2* PTV identified among controls.

We report evidence of PTV association with overall breast cancer risk for *BRCA2* and *ATM* with adjusted ORs of 9.75 (1.81–52.69 95% CI, *p*-value = 0.0081) and 7.61 (1.32–43.97 95% CI, *p*-value = 0.023) (Figure 1; Table 2, Supplementary Table S3). Association with overall breast cancer is also depicted for PTVs in *PALB2* with adjusted ORs of 16.14 (0.85–305.14 95% CI, *p*-value = 0.064), although not statistically significant (Figure 1; Table 2, Supplementary Table S3). For other genes included in the panel, the evidence for an association between overall breast cancer and PTVs did not reach statistical significance (Figure 1; Table 2, Supplementary Table S3).

Breast cancer cases with PTVs in *BRCA1* and *BRCA2* had a relatively younger age at diagnosis (46.7 ± 10.4 sd) compared to



cases without PTVs in *BRCA1* and *BRCA2* (51.6 ± 9.3 sd, Wilcoxon rank sum test p -value = 0.046) or cases with PTVs in genes other than *BRCA1* and *BRCA2* (53 ± 10.9 sd, two-sample t -test p -value = 0.051). The associations with breast cancer overall for both participants diagnosed or recruited at an age earlier or later than 50 years did not reach statistical significance, except for *BRCA2* PTV-carriers who were at an increased risk of the disease if diagnosed at an age later than 50 years (Supplementary Table S4). Analysis by family history of breast cancer (first-degree relatives) revealed that the prevalence of PTVs among patients with a family history of breast cancer (8.23%, $n = 13/158$) was about two times the frequency reported among patients with no family history of breast cancer (3.56%, $n = 29/815$; p -value = 0.015). To investigate the influence of a family history of breast cancer, analysis was conducted separately for cases with and without a first-degree relative with breast cancer. Among participants with family history of breast cancer, PTVs in *ATM* (p -value = 0.002), *BRCA2* (p -value = 0.005), *BRCA1* (p -value = 0.046), *PALB2* (p -value = 0.039) and *RAD50* (p -value = 0.044) were significantly associated with increased risk of breast cancer. The exclusion of breast cancer patients with a family history of breast cancer had a minor impact on PTV association with overall breast cancer risk (i.e., *BRCA2* adjusted OR of 8.74; 1.57-48.75 95% CI, p -value = 0.013) (Supplementary Table S5).

Protein-truncating variants in *BRCA2* were strongly associated with an increased risk of ER-positive and triple-negative breast cancer with adjusted ORs of 10.18 (1.77-58.55 95% CI, p -value = 0.009) and 10.14 (1.08-94.84 95% CI, p -value = 0.042), respectively. Protein-truncating variants in *BRCA1* were strongly associated with an increased risk of ER-negative breast cancer with adjusted ORs of 20.73 (2.04-210.69 95% CI, p -value = 0.0104). Protein-truncating variants in *ATM* were associated with an increased risk of both

ER-negative and ER-positive disease with adjusted ORs of 12.55 (1.33-118.68 95% CI, p -value = 0.027) and 7.47 (1.09-51.23 95% CI, p -value = 0.041), respectively. Finally, PTVs in the *PALB2* gene were associated with an increased risk of ER-negative breast cancer with adjusted ORs of 44.23 (1.78-1098.24 95% CI, p -value = 0.021) (Supplementary Table S3).

Odds ratios decreased significantly with increasing age for *BRCA2* with ORs of 0.94 (0.89-0.99 95% CI, p -value = 0.013) (Supplementary Table S6). Estimated cumulative risks of breast cancer in the absence of other events were calculated by combining age-specific odds ratios with population incidence rates for Cyprus (2020) (Figure 2). For carriers of PTVs in *BRCA2* and *ATM* the estimated cumulative risks by 80 years of age exceeded the 30% threshold for high risk, as defined by the NICE (National Institute for Health and Care Excellence) surveillance screening guidelines (NICE, 2019).

3.2 Rare missense variants

Among 990 breast cancer cases and 1,094 controls, we identified 380 unique rare missense variants in 50.40% of cases ($n = 499/990$) and 41.77% of controls ($n = 457/1,094$) (Supplementary Table S2). Of these, 147 unique rare missense variants were detected in the established breast cancer susceptibility genes, among 195 out of 990 cases (19.70%) and 188 out of 1,094 controls (17.18%). None of the detected rare missense variants were classified as pathogenic.

Rare missense variants in *BRCA1* were associated with an increased risk of overall breast cancer with an adjusted OR of 2.4 (1.14-5.08 95% CI, p -value = 0.022) (Figure 3). In the subtype-stratified analyses, rare missense variants in *BRCA1* were associated with an increased risk of both ER-negative and ER-positive disease with adjusted ORs of 3.56 (1.15-11.01 95% CI, p -value = 0.028) and




FIGURE 2

Estimated cumulative risk of breast cancer associated with protein-truncating variants in genes with significant evidence of an association with breast cancer overall. Cumulative risks of breast cancer in the absence of other events were calculated by combining age-specific odds ratios with population incidence rates for Cyprus (2020) as a baseline. The error bars indicate 95% confidence intervals.


2.77 (1.21–6.38 95% CI, p -value = 0.016), respectively (Supplementary Table S7, Figure 3). Increased risk of triple-negative breast cancer was observed for carriers of rare missense variants in *PALB2* with an adjusted OR of 5.79 (1.32–25.29 95% CI, p -value = 0.020, Figure 3).

For missense variants in aggregate, the evidence for an association between overall breast cancer and any protein domain did not reach statistical significance. However, there was a significantly increased risk of ER-negative breast cancer associated with variants located within the *BRCA1* Zinc-Finger, *ATM* FAT, *PALB2* WD1 and *CHEK2* FHA domains. In addition, rare missense variants within the *ATM* PI3L/PI4K catalytic domain demonstrated an association with an increased risk of ER-positive disease. Furthermore, rare missense variants within *PALB2* domains WD1, domain for stimulation of POLH DNA synthesis and domain for interaction with RAD51, *BRCA2* and *POLH* were significantly associated with increased risk of triple-negative breast cancer. Detailed results from the domain-specific analysis are shown in Supplementary Table S8.

4 Discussion

This study evaluates the prevalence of protein-truncating and rare missense variants in putative breast cancer susceptibility genes and estimates population-specific risks of breast cancer in a large case-control dataset of breast cancer in Cyprus. We used panel sequencing data from 990 breast cancer cases unselected for family history of breast and/or ovarian cancer or age at disease diagnosis and 1,094 age-matched controls, generated as part of the Breast Cancer Association Consortium (BCAC) BRIDGES project (Dorling et al., 2021).

It is generally estimated that around 5%–6% of breast cancer cases and 1%–2% of the general population, harbor PVs in established breast cancer susceptibility genes (Dorling et al., 2021; Hu et al., 2021; Southey et al., 2021). Among breast cancer patients the most prevalent occur in *BRCA2*, *CHEK2*, *BRCA1* and *ATM* (Dorling et al., 2021; Hu et al., 2021). Here, we report that 3.54% of breast cancer cases and 0.37% of controls in Cyprus are positive for PTVs in the established breast cancer susceptibility genes



(Dorling et al., 2021). Among patients and the established breast cancer susceptibility genes, PTVs in *BRCA2* and *ATM*, followed by *PALB2*, and *BRCA1*, were the most prevalent.

The prevalence of PVs in established breast cancer susceptibility genes possesses substantial ethnic and geographic disparities (Yadav et al., 2021). In Cyprus, unique founder PVs and more frequent *BRCA2* PVs have been observed compared to other countries (Hadjisavvas et al., 2004; Loizidou et al., 2017). Protein-truncating variants in *BRCA2* were the most prevalent in our study (1.82%), with the founder *BRCA2* c.8756delG PTV being detected in ten breast cancer cases (1.01%) which corresponds to more than half of the *BRCA2* PTVs observed among cases. Furthermore, *BRCA2* PTVs were associated with a high risk of breast cancer overall, ER-positive and triple-negative disease and exceeded the 80-year cumulative risk threshold for high risk (30%), as defined by the NICE surveillance screening guidelines ((NICE) 2019). The cumulative risk estimates for *BRCA2* PTVs in Cyprus are higher compared to risks reported by population- (Dorling et al., 2021; Hu et al., 2021) and family-based studies (Kuchenbaecker et al., 2017). However, it is consistent with cumulative risk estimates published by Kuchenbaecker et al. (2017).

Protein-truncating variants in *BRCA1* generally confer around 8 to 10-fold increased risk of breast cancer (Antoniou et al., 2003; Kuchenbaecker et al., 2017; Dorling et al., 2021; Hu et al., 2021). In our study, *BRCA1* PTVs showed weak associations with overall breast cancer risk ($p > 0.05$). However, *BRCA1* was associated with an increased risk of ER-negative disease and was identified as a high-risk gene among case patients who had a first-degree relative with breast cancer. Moreover, breast cancer patients with PTVs in *BRCA1* and *BRCA2* had a relatively younger age at diagnosis compared to cases without PTVs in *BRCA1* and *BRCA2* or cases with PTVs in genes other than *BRCA1* and *BRCA2*. These findings are consistent with recent data suggesting that the prevalence of PVs in genes other

than *BRCA1* and *BRCA2* does not depend on age at diagnosis (Tung et al., 2016; Buys et al., 2017).

Among the established breast cancer susceptibility genes, *ATM* yielded an odds ratio of approximately 8 for breast cancer overall and its estimated cumulative risks by 80 years of age exceeded the 30% threshold for high risk [(NICE) 2019], compared to published moderate-risk estimates for *ATM* PTVs (Dorling et al., 2021). Although, if validated in a larger case-control series of breast cancer in Cyprus, it will be of clinical importance.

Pathogenic variants in *PALB2* were previously identified as high- and moderate-risk in the large-scale population-based BRIDGES (Dorling et al., 2021) and CARRIERS projects (Hu et al., 2021). Here we report a possible association of *PALB2* PTVs with high risk of breast cancer overall ($p = 0.06$) and ER-negative disease ($p < 0.05$). However, among cases with a family history of breast cancer, PTVs in *PALB2* were significantly associated with a high risk of disease ($p < 0.05$), a finding consistent with reported associations (Yang et al., 2020; Hu et al., 2021). Furthermore, according to Cybulski et al. (2015) it is estimated that 34% of breast cancer patients with a germline *PALB2* PV have a triple-negative phenotype. We have recently reported that among 163 *BRCA*-negative triple-negative breast cancer patients in Cyprus, 4.3% are positive for PVs in *PALB2* (Zanti et al., 2020), whereas *PALB2* PVs consisted 87.5% of the PVs detected using a panel of 94 cancer susceptibility genes. In the analysis presented here, triple-negative breast cancer patients did not carry any PTVs in *PALB2*. This may be due to the limited number of triple-negative breast cancer cases in our dataset. Hence, additional studies are required to draw more definite conclusions.

It is estimated that variants of uncertain clinical significance (VUS) account for around 30%–40% of the total number of variants identified in gene-panel sequencing studies (Tung et al., 2016; Buys et al., 2017; Federici and Soddu, 2020). Among all women and genes tested, we report a 45.65% prevalence of unclassified rare missense

variants. Of these, 19.70% of breast cancer cases and 17.18% of controls had at least one rare missense variant detected in the established breast cancer susceptibility genes (Dorling et al., 2021). This is consistent with the frequency reported in the large-scale CARRIERS project (Hu et al., 2021). We further demonstrate that rare missense variants in *BRCA1* were associated with an increased risk of breast cancer overall. In addition, rare missense variants in *PALB2* were associated with a moderate risk of triple-negative breast cancer. For missense variants in aggregate, rare missense variants in specific domains in *BRCA1*, *ATM*, *CHEK2*, and *PALB2* were significantly associated with increased risk of certain breast cancer subtypes. However, a possible caveat that should be recognized is the potential presence of missense pathogenic variants at an allele frequency higher than 0.001 which were not included in the current analyses.

Overall, we report that 3.54% of breast cancer cases in Cyprus are positive for PTVs in the established breast cancer susceptibility genes. We further provide population-specific evidence for the association of *BRCA2* and *ATM* PTVs with overall breast cancer risk, and ER-negative breast cancer for *PALB2* PTVs. Among the established breast cancer susceptibility genes, the most prevalent PTVs occurred in the *BRCA2* and *ATM*, followed by *PALB2*, and *BRCA1*. Finally, we confirm the effect of family history, age at diagnosis and tumor subtype as critical factors important for risk stratification of women with breast cancer in the general population of Cyprus. These results, in combination with other risk factors, may have important clinical implications for women who undergo genetic testing for breast cancer susceptibility and be beneficial for a substantial proportion of breast cancer patients in Cyprus.

Data availability statement

Carriers of variants included in the BRIDGES project can be found here: https://databases.lovd.nl/shared/screenings#order=id%20CASC&search_owned_by_=BRIDGES%20consortium&page_size=100&page=1 https://databases.lovd.nl/shared/view/BRCA1#object_id=VariantOnTranscript%2CVariantOnGenome%2CScreening%2CIndividual&id=BRCA1#VariantOnTranscript%2FDNA%2CASC&search_transcriptid=00003478&search_owned_by_=BRIDGES%20consortium&page_size=100&page=1 <https://bcac.ccg.medschl.cam.ac.uk/bcacdata/bridges/>. Requests for raw data can be made to the Data Access Coordination Committee (DACC) of BCAC (<http://bcac.ccg.medschl.cam.ac.uk/>).

Ethics statement

The study was approved by the National Bioethics Committee of Cyprus, and all participants provided signed informed consent (Approval No, EEBK/EII/2016/38).

Author contributions

MZ and KM drafted the manuscript. ML, MP, and AH recruited samples and collected clinical information. DE and PD obtained funding for the BRIDGES project. MZ, DM, LD, and JD performed

statistical, bioinformatics and variant annotation analysis. All authors contributed to the article and approved the submitted version.

Funding

BCAC is funded by the European Union's Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and the PERSPECTIVE I&I project, funded by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the Ministère de l'Économie et de l'Innovation du Québec through Genome Québec, the Quebec Breast Cancer Foundation. The EU Horizon 2020 Research and Innovation Programme funding source had no role in study design, data collection, data analysis, data interpretation or writing of the report. Additional funding for BCAC is provided via the Confluence project which is funded with intramural funds from the National Cancer Institute Intramural Research Program, National Institutes of Health. The BRIDGES panel sequencing was supported by the European Union Horizon 2020 research and innovation program BRIDGES (grant number, 634935) and the Wellcome Trust (v203477/Z/16/Z). The MASTOS study was supported by "Cyprus Research Promotion Foundation" grants 0104/13 and 0104/17, and the Cyprus Institute of Neurology and Genetics.

Acknowledgments

We thank all the study participants and express appreciation to the doctors: Yiola Marcou, Eleni Kakouri, Panayiotis Papadopoulos, Simon Malas and Maria Daniel, as well as to all the nurses and volunteers who provided valuable help towards the recruitment of the study participants.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fgene.2023.1248492/full#supplementary-material>

References

- Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. *Am. J. Hum. Genet.* 72 (5), 1117–1130. doi:10.1086/375033
- Buys, S. S., Sandbach, J. F., Gammon, A., Patel, G., Kidd, J., Brown, K. L., et al. (2017). A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. *Cancer* 123 (10), 1721–1730. doi:10.1002/cncr.30498
- Cybulski, C., Kluzniak, W., Huzarski, T., Wokolorczyk, D., Kashyap, A., Jakubowska, A., et al. (2015). Clinical outcomes in women with breast cancer and a PALB2 mutation: A prospective cohort analysis. *Lancet Oncol.* 16 (6), 638–644. doi:10.1016/S1470-2045(15)70142-7
- Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., et al. (2021). Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. *J. Natl. Compr. Canc. Netw.* 19 (1), 77–102. doi:10.6004/jnccn.2021.0001
- Dorling, L., Carvalho, S., Allen, J., Gonzalez-Neira, A., Luccarini, C., Wahlstrom, C., et al. (2021). Breast cancer risk genes - association analysis in more than 113,000 women. *N. Engl. J. Med.* 384 (5), 428–439. doi:10.1056/NEJMoa1913948
- Federici, G., and Soddu, S. (2020). Variants of uncertain significance in the era of high-throughput genome sequencing: A lesson from breast and ovary cancers. *J. Exp. Clin. Cancer Res.* 39 (1), 46. doi:10.1186/s13046-020-01554-6
- Fortuno, C., Cipponi, A., Ballinger, M. L., Tavtigian, S. V., Olivier, M., Ruparel, V., et al. (2019). A quantitative model to predict pathogenicity of missense variants in the TP53 gene. *Hum. Mutat.* 40 (6), 788–800. doi:10.1002/humu.23739
- Fortuno, C., Pesaran, T., Dolinsky, J., Yussuf, A., McGoldrick, K., Tavtigian, S. V., et al. (2021). An updated quantitative model to classify missense variants in the TP53 gene: A novel multifactorial strategy. *Hum. Mutat.* 42 (10), 1351–1361. doi:10.1002/humu.24264
- Hadjisavvas, A., Charalambous, E., Adamou, A., Neuhausen, S. L., Christodoulou, C. G., and Kyriacou, K. (2004). Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation. *Cancer Genet. Cytogenet.* 151 (2), 152–156. doi:10.1016/j.cancergencyto.2003.09.020
- Hadjisavvas, A., Loizidou, M. A., Middleton, N., Michael, T., Papachristoforou, R., Kakouri, E., et al. (2010). An investigation of breast cancer risk factors in Cyprus: A case control study. *BMC Cancer* 10, 447. doi:10.1186/1471-2407-10-447
- Hu, C., Hart, S. N., Gnanaolivu, R., Huang, H., Lee, K. Y., Na, J., et al. (2021). A population-based study of genes previously implicated in breast cancer. *N. Engl. J. Med.* 384 (5), 440–451. doi:10.1056/NEJMoa2005936
- Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M., Roos-Bloom, M. J., et al. (2017). Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *JAMA* 317 (23), 2402–2416. doi:10.1001/jama.2017.7112
- Loizidou, M. A., Michael, T., Neuhausen, S. L., Newbold, R. F., Marcou, Y., Kakouri, E., et al. (2008). Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2 and XRCC3 and risk of breast cancer in Cyprus. *Breast Cancer Res. Treat.* 112 (3), 575–579. doi:10.1007/s10549-007-9881-4
- Loizidou, M. A., Hadjisavvas, A., Pirpa, P., Spanou, E., Delikurt, T., Tanteles, G. A., et al. (2017). BRCA1 and BRCA2 mutation testing in Cyprus: a population based study. *Clin. Genet.* 91 (4), 611–615. doi:10.1111/cge.12886
- National Institute for Health and Care Excellence (NICE) (2019). *Familial breast cancer: Classification, care and managing breast cancer and related risks in people with a family history of breast cancer*. London: National Institute for Health and Care Excellence.
- Pilie, P. G., Tang, C., Mills, G. B., and Yap, T. A. (2019). State-of-the-art strategies for targeting the DNA damage response in cancer. *Nat. Rev. Clin. Oncol.* 16 (2), 81–104. doi:10.1038/s41571-018-0114-z
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., et al. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. *Genet. Med.* 17 (5), 405–424. doi:10.1038/gim.2015.30
- Ruark, E., Snape, K., Humburg, P., Loveday, C., Bajrami, I., Brough, R., et al. (2013). Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. *Nature* 493 (7432), 406–410. doi:10.1038/nature11725
- Schmidt, M. K., Hogervorst, F., van Hien, R., Cornelissen, S., Broeks, A., Adank, M. A., et al. (2016). Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. *J. Clin. Oncol.* 34 (23), 2750–2760. doi:10.1200/JCO.2016.66.5844
- Southey, M. C., Dowty, J. G., Riaz, M., Steen, J. A., Renault, A. L., Tucker, K., et al. (2021). Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing. *NPJ Breast Cancer* 7 (1), 153. doi:10.1038/s41523-021-00360-3
- Spurdle, A. B., Healey, S., Devereau, A., Hogervorst, F. B., Monteiro, A. N., Nathanson, K. L., et al. (2012). ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. *Hum. Mutat.* 33 (1), 2–7. doi:10.1002/humu.21628
- Tung, N., Lin, N. U., Kidd, J., Allen, B. A., Singh, N., Wenstrup, R. J., et al. (2016). Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. *J. Clin. Oncol.* 34 (13), 1460–1468. doi:10.1200/JCO.2015.65.0747
- Wang, K., Li, M., and Hakonarson, H. (2010). Annovar: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 38 (16), e164. doi:10.1093/nar/gkq603
- Yadav, S., LaDuca, H., Polley, E. C., Hu, C., Niguidula, N., Shimelis, H., et al. (2021). Racial and ethnic differences in multigene hereditary cancer panel test results for women with breast cancer. *J. Natl. Cancer Inst.* 113 (10), 1429–1433. doi:10.1093/jnci/djaa167
- Yang, X., Leslie, G., Doroszuk, A., Schneider, S., Allen, J., Decker, B., et al. (2020). Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. *J. Clin. Oncol.* 38 (7), 674–685. doi:10.1200/JCO.19.01907
- Zanti, M., Loizidou, M. A., Michailidou, K., Pirpa, P., Machattou, C., Marcou, Y., et al. (2020). NGS panel testing of triple-negative breast cancer patients in Cyprus: A study of BRCA-negative cases. *Cancers (Basel)* 12 (11), 3140. doi:10.3390/cancers12113140